PharmaMar’s Virology Unit has been created to discover, to develop and to incorporate new therapeutic tools for viral diseases, for which there are, to date, no effective treatments.

The current priority of our Unit focuses on characterizing an effective treatment for SARS-CoV-2. In this context, we are actively developing plitidepsin, a potent antiviral agent as a therapeutic model in patients with COVID-19.

“The world is experiencing different types of virus pandemics in different geographic areas. They are becoming increasingly important and are having a huge social and economic impact. At present, we live with viruses in animals that are susceptible to jump species, ending up affecting human beings. For this reason, we need to be prepared to fight the viruses that are currently affecting and seriously impacting society, along with the viruses that could appear in the near future. What has happened with SARS-CoV-2, could happen again.”

José María Fernández, Ph.D., President of PharmaMar.